Skip to main content

Efficacy of Investigational COVID-19 CVP and Pathogen Reduction Technology on Blood Components

From the 2021 Joint Annual Meeting (recorded 6/30/2021)
Presented by Marionette Cortez, AHI,MT(AMT) and Marcia Firmani, Ph.D., MT(ASCP)MB & Francisco Rentas, PhD, SBB

This session contains 2 presentations:

  • The Efficacy of Investigational COVID-19 Convalescent Plasma for Treatment of Hospitalized Critically-Ill COVID-19 Patients
    • This presentation will describe the step-by-step procedure for supplying COVID-19 convalescent plasma for COVID-19 patients from our local blood supplier. The convalescent plasma that is being given was granted emergency use authorization status by the FDA .The convalescent plasma is from donors who have fully recovered from SARS-CoV-2 virus. The donors must qualify as a blood donor fully screened and donate fresh frozen plasma by pheresis, which is then labelled high titer convalescent plasma.
  • The Use and Feasibility of Pathogen Reduction Technology on Several Blood Components
    • The use of pathogen reduction (PR) technology is a proactive approach to improve blood component transfusion safety. In this presentation, we will discuss PR technology and results from our studies using PR on several blood products, including whole blood, cryoprecipitate, and frozen red blood cells.
At the conclusion of these presentations, participants will be able to:
  • Identify if a Covid19 patient meet the criteria to receive Convalescent Plasma.
    Identify if Convalescent Plasma is truly effective treatment for Covid19 patients.
    Identify the components of Convalescent plasma and why it was granted Emergency Use Authorization status by the FDA.
  • Discuss current pathogen reduction technologies (PRT) for use in transfusion medicine
    Evaluate data generated from recent studies using PRT on whole blood, cryoprecipitate and frozen red blood cells
    Discuss the future feasibility of using PRT on various blood components

ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of General (Immunohematology) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.